Prevalence of genotypic drug resistance among a cohort of HIV-infected newborns

Journal of Acquired Immune Deficiency Syndromes

Volumn 32, Issue 3, 2003, Pages 292-297

  Parker, Monica M ^a   Wade, Nancy ^b   Lloyd Jr , Robert M ^c   Birkhead, Guthrie S ^b   Gallagher, Brian K ^b   Cheku, Babu ^b   Sullivan, Timothy ^a   Taylor, Jill ^a  

^a WADSWORTH CENTER   (United States)

^b NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^c Visible0 Genetics Inc   (United States)

Author keywords

Drug resistance; Genotype; HIV 1; Perinata; Prevalence

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG RESISTANCE; FEMALE; GENETIC ANALYSIS; GENETIC RESISTANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NEWBORN DISEASE; PERINATAL PERIOD; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS MUTATION;

ANTI-HIV AGENTS; COHORT STUDIES; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; INFANT; INFANT, NEWBORN; MALE; NEW YORK; PERINATAL CARE; PROVIRUSES; RETROSPECTIVE STUDIES;

EID: 0037340667     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200303010-00008     Document Type: Article

References (28)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternalinfant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-80.
2. US Public Health Service Task Force. Recommendations of the US Public Health Service Task Force on use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1994;43:1-20.
3. Wade N, Zielinski M, Glaros R, et al. Trends in prevention of perinatal HIV transmission, New York State (NYS), 1997-1999 [abstract 701]. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 4-8, 2001.
4. Perinatal HIV Guidelines Working Group. US Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. 2002.
5. Kartsonis NA, D'Aquila RT. Clinical monitoring of HIV-1 infection in the ERA of antiretroviral resistance testing. Infect Dis Clin North Am 2000;14:879-99.
6. Colgrove RC, Pitt J, Chung PH, et al. Selective vertical transmission of HIV-1 antiretroviral resistance mutations. AIDS 1998;12: 2281-8.
7. Welles SL, Pitt J, Colgrove R, et al. HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group. AIDS 2000;14:263-71.
8. Principi N, Marchisio P, De Pasquale MP, et al. HIV-1 reverse transcriptase codon 215 mutation and clinical outcome in children treated with zidovudine. AIDS Res Hum Retroviruses 1994;10: 721-6.
9. Eshleman SH, Krogstad P, Jackson JB, et al. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377). J Infect Dis 2001;183:1732-8.
10. Little SJ. Is transmitted drug resistance in HIV on the rise? It seems so. BMJ 2001;322:1074-5.
11. Charbonneau TT, Wade NA, Weiner L, et al. Vertical transmission of HIV in New York State: a basis for statewide testing of newborns. AIDS Patient Care STDS 1997;11:227-36.
12. Kantor R, Machekano R, Gonzales MJ, et al. Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Res 2001;29:296-9.
13. Cooper ER, Christiansen D, Lloyd RM, et al. Comparison of HIV-1 proviral DNA and plasma RNA genotyping and its utility in the selection of antiretroviral therapy in children. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, February 4-8, 2001.
14. Johnson VA, Petropoulos CJ, Woods CR, et al. Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. J Infect Dis 2001; 183:1688-93.
15. Nolan M, Fowler MG, Mofenson LM. Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of anti-retroviral resistance. J Acquir Immune Defic Syndr 2002;30: 216-29.
16. Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998;177:557-64.
17. Masquelier B, Chaix ML, Burgard M, et al. Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort. J Acquir Immune Defic Syndr 2001;27:99-104.
18. Palumbo P, Holland B, Dobbs T, et al. Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and clades. J Infect Dis 2001;184:1120-6.
19. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001;285:2083-93.
20. Perno CF, Cozzi-Lepri A, Balotta C, et al. Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis 2001;184:983-91.
21. Little SJ, Routy JP, Daar ES, et al. Antiretroviral drug susceptibility and response to initial therapy among recently HIV-infected subjects in North America. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 4-8, 2001.
22. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001;322: 1087-8.
23. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA panel. JAMA 2000;283: 2417-26.
24. Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR Morb Mortal Wkly Rep 1998;47:1-43.
25. Miller V. Structured treatment interruptions in antiretroviral management of HIV - 1. Curr Opin Infect Dis 2001;14:29-37.
26. Pasquier C, Cayrou C, Blancher A, et al. Molecular evidence for mother-to-child transmission of multiple variants by analysis of RNA and DNA sequences of human immunodeficiency virus type 1. J Virol 1998;72:8493-501.
27. Dickover RE, Garratty EM, Plaeger S, et al. Perinatal transmission of major, minor, and multiple maternal human immunodeficiency virus type 1 variants in utero and intrapartum. J Virol 2001;75: 2194-203.
28. Van Tine BA, Shaw GM, Aldrovandi G. Mother-to-infant transmission of the human immunodeficiency virus during primary infection. N Engl J Med 1999;341:1548.